Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial.
Piliang M, Lynde C, King B, Mirmirani P, Sinclair R, Senna M, Forman S, Bordone L, De La Cueva Dobao P, Wolk R, Zwillich SH, Tran H, Wajsbrot D, Ahmed HM, Takiya L. Piliang M, et al. Among authors: takiya l. J Am Acad Dermatol. 2025 Feb;92(2):276-284. doi: 10.1016/j.jaad.2024.09.064. Epub 2024 Oct 17. J Am Acad Dermatol. 2025. PMID: 39423930 Free article. Clinical Trial.
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.
Mesinkovska N, King B, Zhang X, Guttman-Yassky E, Magnolo N, Sinclair R, Mizuashi M, Shapiro J, Peeva E, Banerjee A, Takiya L, Cox LA, Wajsbrot D, Kerkmann U, Law E, Wolk R, Schaefer G. Mesinkovska N, et al. Among authors: takiya l. J Dermatol. 2024 Nov;51(11):1414-1424. doi: 10.1111/1346-8138.17442. Epub 2024 Sep 27. J Dermatol. 2024. PMID: 39328096 Clinical Trial.
Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H, Harada K, Law E, Wajsbrot D, Takiya L, Zwillich SH, Wolk R, Tran H. Hordinsky M, et al. Among authors: takiya l. Pediatr Dermatol. 2023 Nov-Dec;40(6):1003-1009. doi: 10.1111/pde.15378. Epub 2023 Jul 17. Pediatr Dermatol. 2023. PMID: 37455588 Clinical Trial.
30 results